PL3234597T3 - Białka szlaku sygnałowego wnt i ich zastosowanie w diagnostyce i leczeniu zaburzeń hipopigmentacji - Google Patents

Białka szlaku sygnałowego wnt i ich zastosowanie w diagnostyce i leczeniu zaburzeń hipopigmentacji

Info

Publication number
PL3234597T3
PL3234597T3 PL15813367T PL15813367T PL3234597T3 PL 3234597 T3 PL3234597 T3 PL 3234597T3 PL 15813367 T PL15813367 T PL 15813367T PL 15813367 T PL15813367 T PL 15813367T PL 3234597 T3 PL3234597 T3 PL 3234597T3
Authority
PL
Poland
Prior art keywords
diagnostic
proteins
treatment
signaling pathway
wnt signaling
Prior art date
Application number
PL15813367T
Other languages
English (en)
Inventor
Thierry Passeron
Florence JOLY
Original Assignee
Inserm - Institut National De La Santé Et De La Recherche Médicale
Université Côte d'Azur
Chu De Nice
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inserm - Institut National De La Santé Et De La Recherche Médicale, Université Côte d'Azur, Chu De Nice filed Critical Inserm - Institut National De La Santé Et De La Recherche Médicale
Publication of PL3234597T3 publication Critical patent/PL3234597T3/pl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/14Alkali metal chlorides; Alkaline earth metal chlorides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/20Dermatological disorders
    • G01N2800/207Pigmentation disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL15813367T 2014-12-18 2015-12-16 Białka szlaku sygnałowego wnt i ich zastosowanie w diagnostyce i leczeniu zaburzeń hipopigmentacji PL3234597T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14307089 2014-12-18
EP15813367.8A EP3234597B1 (en) 2014-12-18 2015-12-16 Proteins of the wnt signaling pathway and uses thereof in the diagnostic and treatment of hypopigmentation disorders
PCT/EP2015/080066 WO2016097035A1 (en) 2014-12-18 2015-12-16 Proteins of the wnt signaling pathway and uses thereof in the diagnostic and treatment of hypopigmentation disorders

Publications (1)

Publication Number Publication Date
PL3234597T3 true PL3234597T3 (pl) 2022-03-07

Family

ID=52396377

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15813367T PL3234597T3 (pl) 2014-12-18 2015-12-16 Białka szlaku sygnałowego wnt i ich zastosowanie w diagnostyce i leczeniu zaburzeń hipopigmentacji

Country Status (7)

Country Link
US (2) US10983134B2 (pl)
EP (1) EP3234597B1 (pl)
DK (1) DK3234597T3 (pl)
ES (1) ES2905438T3 (pl)
PL (1) PL3234597T3 (pl)
PT (1) PT3234597T (pl)
WO (1) WO2016097035A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2905438T3 (es) * 2014-12-18 2022-04-08 Inst Nat Sante Rech Med Proteínas de la vía de señalización de WNT y usos de las mismas en el diagnóstico y tratamiento de trastornos de hipopigmentación
WO2022151450A1 (zh) * 2021-01-16 2022-07-21 海口仁术皮肤科门诊部有限公司 毛囊黑素细胞干细胞移植术治疗白癜风的技术方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368131B2 (en) * 2003-02-27 2008-05-06 Supernatural Health, Inc. Method and composition for treating hypopigmentation of the hair and skin
DE202004013006U1 (de) 2004-07-15 2004-11-04 Otto Sauer Achsenfabrik Keilberg Bremseinrichtung mit Bremssattelbefestigung
WO2006078886A2 (en) * 2005-01-18 2006-07-27 Irm Llc Compounds and compositions as wnt signaling pathway modulators
KR20110130282A (ko) * 2010-05-27 2011-12-05 아주대학교산학협력단 Wif-1 조절을 통한 색소 질환 치료용 조성물
KR102031161B1 (ko) * 2011-10-18 2019-10-14 (주)아모레퍼시픽 피부 미백 물질 스크리닝 시스템
KR20130073069A (ko) 2011-12-23 2013-07-03 현대모비스 주식회사 오디오 이상 유무 자가 진단 가능한 음원 재생 장치 및 그 방법
ES2905438T3 (es) * 2014-12-18 2022-04-08 Inst Nat Sante Rech Med Proteínas de la vía de señalización de WNT y usos de las mismas en el diagnóstico y tratamiento de trastornos de hipopigmentación
WO2016097031A1 (en) * 2014-12-18 2016-06-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Gsk3b and uses thereof in the diagnostic and treatment of hypopigmentation disorders

Also Published As

Publication number Publication date
US20210190800A1 (en) 2021-06-24
PT3234597T (pt) 2022-02-15
EP3234597B1 (en) 2021-11-10
US11650214B2 (en) 2023-05-16
US10983134B2 (en) 2021-04-20
US20180180631A1 (en) 2018-06-28
WO2016097035A1 (en) 2016-06-23
WO2016097035A9 (en) 2017-08-24
DK3234597T3 (da) 2022-02-07
ES2905438T3 (es) 2022-04-08
EP3234597A1 (en) 2017-10-25

Similar Documents

Publication Publication Date Title
IL281793A (en) Use of cannabinoids in the treatment of epilepsy
RS60996B1 (sr) Interleukin 15 proteinski kompleks i njegova upotreba
GB201519858D0 (en) Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
GB201411496D0 (en) Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy
IL249580A0 (en) Methods for anesthetizing nerve tissue in the trigeminal nerve pathway and their medical uses
PL3277280T3 (pl) Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych
ZA201704726B (en) Peptides and their use in the treatment of skin
IL251904A0 (en) Epilimod for use in the treatment of melanoma
GB201515986D0 (en) Use of cannabinoids in the treatment of mental disorders
HUE062784T2 (hu) Indolinon vegyületek és alkalmazásuk fibrotikus betegségek kezelésében
PT3160464T (pt) 6-hidroxibuspirona para uso no tratamento de transtornos do movimento
PT3177599T (pt) Análogos fumarato e utilizações dos mesmos no tratamento de uma doença autoimune ou uma doença inflamatória
GB201423272D0 (en) The combination for anti-wrinkle and soothing the skin
GB201404372D0 (en) Assay and treatment
SG11201704486TA (en) Improvements in and relating to the treatment of matrices and/or the contents of matrices
GB201500500D0 (en) Biological materials and therapeutic uses thereof
HK1217913A1 (zh) 阿地米屈在治療上皮功能障礙中的用途
HK1209363A1 (en) Use of lactobacillus crispatus in the treatment or prevention of rheumatoid arthritis or related diseases
PL3135337T3 (pl) Urządzenie do relaksu i odnowy ciała
PL3234597T3 (pl) Białka szlaku sygnałowego wnt i ich zastosowanie w diagnostyce i leczeniu zaburzeń hipopigmentacji
HK1244821A1 (zh) 用於治療和診斷1型糖尿病中使用的肽
IL251605B (en) Use of protein in predicting intra-corporeal phenomena
GB201423270D0 (en) The combination for soothing and repair of the skin
GB201411616D0 (en) Diagnosis and treatment of neurodegenerative disorders